← Eichor
Condition: The First Line Treatment Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: The First Line Treatment

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Phase 3 · 2 location(s) · Shanghai Yizhong Pharmaceutical Co., Ltd. · NCT06752811A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic
Phase 1 · 26 location(s) · R-Pharm · NCT07543744PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's
Phase 4 · 20 location(s) · University of Calgary · NCT05928039Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients
Phase 2 · 8 location(s) · Institut du Cancer de Montpellier - Val d'Aurelle · NCT05065801Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07407166Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT07293403Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Phase 2 · 18 location(s) · VA Office of Research and Development · NCT04038502The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line
Phase 2 · 1 location(s) · Zhejiang University · NCT07257653Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With
Phase 3 · 3 location(s) · Beijing Shenogen Biomedical Co., Ltd · NCT05594927A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Ca
Phase 3 · 205 location(s) · Merus B.V. · NCT06525220ORal Aminaphtone and Combined LidocainE
Phase N/A · 1 location(s) · Treviso Regional Hospital · NCT07026513A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensi
Phase N/A · 13 location(s) · AbbVie · NCT05317494Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Can
NA · 1 location(s) · Oncomedics · NCT05299840A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.
Phase 3 · 1 location(s) · Sinocelltech Ltd. · NCT07362459Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fet
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT07289997JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit
Phase 3 · 37 location(s) · Allist Pharmaceuticals, Inc. · NCT06416410A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With
EARLY_Phase 1 · 1 location(s) · People's Hospital of Quzhou · NCT07647094The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06503276Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment
NA · 51 location(s) · UNICANCER · NCT06505018Cryoablation Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-L
Phase 2 · 1 location(s) · Ruijin Hospital · NCT07306286Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer.
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT05624099Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
Phase 3 · 1 location(s) · Fudan University · NCT05806060FDG PET-CT in Advanced Breast Cancer
Phase N/A · 1 location(s) · Samsung Medical Center · NCT07173868A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplan
Phase 2 · 40 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015242A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 1 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07478302Clinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatme
Phase 3 · 5 location(s) · Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · NCT05653453DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer
Phase 2 · 2 location(s) · Jochen Lorch · NCT06959641Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed
Phase 3 · 36 location(s) · Sanofi · NCT07007962
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.